Thursday 18 May 2023
08:00 - 08:45 Educational Session 3
08:00
Normal sympathetic nervous system development: From organoid and zebrafish to humanized mouse
Susanne Schlisio, Sweden
08:20
Heterogeneity in clinical course of NB: broad overview: clinical behaviour - disease course
Meredith Irwin, Canada
09:00 - 10:00 Plenary session 6: Genetic drivers of resistance and relapse
Sponsored by Neuroblastoma UK, Moderators: Gudrun Schleiermacher, France & John Maris, United States
09:00
PS6.1 Investigating neuroblastoma evolution by matched diagnosis, relapse and cfDNA sequencing as part of the Stratified Medicine for Paediatrics study (SMPaeds)
Sally George, UK
09:15
PS6.2 The transcriptional co-repressor Runx1t1 is essential for N-Myc-driven neuroblastoma tumorigenesis
Murray Norris, Australia
09:30
PS6.3 Frequency and clinical significance of subclonal and clonal driver mutations in high-risk neuroblastomas at diagnosis: A Children’s Oncology Group Study.
Esther Berko, United States
09:45
PS6.4 Genomic landscape of a national neuroblastoma relapse cohort and its implications
Pascal Kohmann, Germany
10:00 - 10:45 Keynote Lecture 3
Moderator: Katleen de Preter, Belgium
10:00
Organoid cellular cancer immunity models in motion
Anne Rios, the Netherlands
10:45
10:45 - 11:15 Coffee break
11:15 - 12:05 Parallel session 15: How patient advocates can help improve the survival of children with neuroblastoma
Sponsored by Villa Joep, Solving kids' Cancer and Neuroblastoma UK
11:15 - 12:05 Parallel session 16: Genetic drivers of resistance and relapse
Moderators: Daniel Bexell, Sweden & Esther Berko, Israel
11:15
O16.1 Loss of p16INK4a in neuroblastoma induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors
Marlinde van den Boogaard, the Netherlands
11:27
O16.2 Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing in Neuroblastoma
Jaydutt Bhalshankar, France
11:39
O16.3 Direct targeting of RAS via small-molecule inhibition in RAS-driven and lorlatinib-resistant ALK-driven high-risk neuroblastomas
Mark Gerelus, United States
11:51
O16.4 A genetic study of paired diagnosis and relapse neuroblastoma samples identifies a novel relapse-specific mutational signature
Lisa Allinson, UK
12:05 - 12:20 Rapid Fire session 2B
Moderator: Katleen de Preter, Belgium
12:05
P195 Nucleosome footprinting enables inference of expression profiles in circulating tumor DNA from neuroblastoma patients
Yasmine Iddir, France
12:06
P194 The C57 BL/6 Th-ALKF1174L/MYCN genetically-engineered murine model of high-risk neuroblastoma enables the preclinical study of metastatic drug resistant relapse
Lizzie Tucker, UK
12:07
P196 Detection of epigenetic cell states in cell-free DNA of high-risk neuroblastoma patients
Lotte Cornelli, Belgium
12:08
P193 Comprehensive allelic series of ATRX In-Frame-Fusions in neuroblastoma reveals neomorphic protein functions
Sina Jostes, United States
12:09
P299 Surgical Outcome of A Nationwide Phase II Study of Delayed Local Treatment for Children with High-risk Neuroblastoma (JN-H-11)
Akihiro Yoneda, Japan
12:10
P300 Late disappearance of minimal residual disease after KIR-ligand mismatched allogeneic CBT suggests KIR mismatched NK cell activity to Neuroblastoma
Nobuhiro Nishio, Japan
12:11
P272 Modeling strategies for survival in Neuroblastoma: focus on long-term survival prediction in stage 4 patients >1 year treated within SIOPEN-HR-NBL1
Ulrike Poetschger, Austria
12:12
P326 Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
Jill Deleu, Belgium
12:13
P330 Multiplexing of genomic targets for high-risk neuroblastoma MRD diagnostics using mediator probe PCR chemistry
Anna Schroeer, Germany
12:14
P331 Longitudinal cell-free DNA analysis in patients with high-risk neuroblastoma is suitable for early relapse and actionable target detection
Marco Lodrini, Germany
12:20
12:20 - 13:50 Lunch & Poster Session Group D
Posters with reference P271 until P350
12:20 - 13:50 Lunch meeting I: Managing bone and bone marrow involvement in neuroblastoma with anti-GD2 therapy
This activity is supported by an independent educational grant from Y-mAbs Therapeutics, Inc.
12:20
Welcome and introduction
Daniel Morgenstern
12:25
Anti-GD2 strategies for high-risk neuroblastoma
Juliet Gray
12:35
Expert presentation: High-risk neuroblastoma with bone and bone marrow involvement
Lieve Tytgat
12:50
Three interactive short patient case challenges
Case challenge 1
Patient who relapses during immunotherapy maintenance: What to treat with next?
Juliet Gray
Case challenge 2
Treatment options for primary refractory disease in bone and/or bone marrow
Daniel Morgenstern
Case challenge 3
Treatment options for patients with oligometastatic recurrence on MIBG
Lieve Tytgat
13:35
Future outlook for antibody therapy
Daniel Morgenstern
13:40
Q&A
Moderated by Daniel Morgenstern
13:45
Summary and close
Daniel Morgenstern
12:30 - 13:40 Lunch meeting II: 2035: A High-Risk Neuroblastoma Odyssey
Sponsored by Solving kids' Cancer
12:30
Welcome and introduction
Prof Andy Pearson || Presenters: Leona Knox, Prof Rochelle Bagatelle || Panel: Leona Knox, Nick Bird, Advocate (US), Prof Rochelle Bagatelle, Dr Steve DuBois, Prof Maja Beck, Dr Lucas Moreno
Therapy for children with high-risk neuroblastoma has changed dramatically and outcomes have greatly improved in the past decades, but much remains to be done to increase survival rates and decrease late effects of treatment. To move the field forward and improve outcomes for all children with high-risk neuroblastoma, we must develop a vision for neuroblastoma therapy that extends beyond what is right around the corner, and consider the paradigm shifts that will be required to turn our broad vision into reality. Please join us for an interactive session that will be of interest to laboratory-based scientists, neuroblastoma trialists, clinical care providers and parent advocates as we take a birds’ eye view and challenge ourselves to think expansively about how neuroblastoma will be treated in 2035 … and beyond.
13:50 - 14:50 Plenary session 7: Novel diagnostics: liquid biopsies
Moderators: Steven Dubois, United States & Lieve Tytgat, the Netherlands
13:50
PS7.1 Liquid biopsies for monitoring tumor evolution and pharmacodynamic assessment of vorinostat effects during neuroblastoma therapy
Anne-Florence Blandin, United States
14:05
PS7.2 Quantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) MYCN breakpoints
Annabell Szymansky, Germany
14:20
PS7.3 Application of liquid biopsy approaches in neuroblastoma: Whole-exome sequencing and targeted approaches for diagnostic, prognostic and minimal residual disease detection
Zeinab Van Gestel-fadaie, the Netherlands
14:35
PS7.4 Integrating correlative biology into a phase III clinical trial for high-risk neuroblastoma to study mechanisms of tumor evolution
Gabriela Virdzekova, United States
14:50
Coffee break
15:20 - 16:10 Parallel session 17: Novel diagnostics: imaging
Moderators: Marie Luporsi, France & Mark Gaze, UK
15:20
O17.1 Performing [18F]mFBG Long Axial Field Of View (LAFOV) PET-CT without sedation or general anaesthesia for imaging of children with neuroblastoma
Lise Borgwardt, Denmark
15:32
O17.2 18F-MFBG PET imaging in patients with neuroblastoma: lesion targeting and comparison with MIBG
Shakeel Modak, United States
15:44
O17.3 Prognostic value of tumor heterogeneity in neuroblastoma using pre-treatment MIBG SPECT/CT: is there a place for radiomics?
Marie Luporsi, France
15:56
O17.4 Multispectral short-wave infrared (SWIR) fluorescence imaging as a new versatile tool to enhance intra-operative delineation of tumour margins
Laura Privitera, UK
15:20 - 16:10 Parallel session 18: Immune Therapy
Moderators: Paul Sondel, United States & Jan Molenaar, the Netherlands
15:20
O18.1 Mastering the game of hide and seek: epigenetic modulation as a strategy to increase T-cell immunogenicity of high-risk neuroblastoma
Annelisa Cornel, the Netherlands
15:32
O18.2 Copper chelation disrupts the immunosuppressive neuroblastoma microenvironment to enhance anti-GD2 immunotherapy
Orazio Vittorio, Australia
15:44
O18.3 A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate demonstrates potent cytotoxicity in neuroblastoma (NB) and other ALK-expressing cancers
Alberto Guerra, United States
15:56
O18.4 Targeting neuroblastoma using Aurora-A inhibition and CAR T-cells
Mareike Müller, Germany
16:10
Change rooms
16:20 - 16:45 Scientific highlights ANR2023
16:45 - 17:10 Closing Ceremony
19:00
19:00 - 01:00 Congress dinner + party